Julie M. Cherrington

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Dirk B. Mendel, Alexander Laird, Xiaohua Xin et al. · PubMed · 2003 · 2K citations

Medicine, Oncology, Pharmacology +15

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

Anne-Marie O'Farrell, Tinya J. Abrams, Helene A. Yuen et al. · Blood · 2003 · 857 citations · Full text

Medicine, Oncology, Pharmacology +11

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

Tinya J. Abrams, Leslie B. Lee, Lesley Murray et al. · PubMed · 2003 · 639 citations

Medicine, Oncology, Pharmacology +17

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

James G. Christensen, Randall Schreck, Jon Burrows et al. · PubMed · 2003 · 497 citations

Medicine, Oncology, Pharmacology +15

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

Alexander Laird, Peter Vajkoczy, Laura K. Shawver et al. · PubMed · 2000 · 497 citations

Medicine, Medicinal Chemistry, Pharmacology +16